Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer

Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer

Abstract Background This study aimed to investigate the factors associated with prolonged progression‐free survival (PFS) (>36 months) of advanced non‐small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations treated with first‐line afatinib. Methods We p...

Full description

Bibliographic Details
Main Authors:	Li‐Chung Chiu, Ping‐Chih Hsu, Chin‐Chou Wang, How‐Wen Ko, Scott Chih‐Hsi Kuo, Jia‐Shiuan Ju, Pi‐Hung Tung, Allen Chung‐Cheng Huang, Cheng‐Ta Yang
Format:	Article
Language:	English
Published:	Wiley 2024-03-01
Series:	Thoracic Cancer
Subjects:	afatinib epidermal growth factor receptor mutation non‐small cell lung cancer progression‐free survival
Online Access:	https://doi.org/10.1111/1759-7714.15212

Similar Items

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
by: Ping-Chih Hsu, et al.
Published: (2020-10-01)

Durable response to afatinib rechallenge in a long‐term survivor of non‐small cell lung cancer harboring EGFR L858R and L747V mutations
by: Mio Kanbe, et al.
Published: (2022-11-01)

Bilateral keratitis associated with afatinib therapy
by: Ya-Tung Liu, et al.
Published: (2024-01-01)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR‐mutated NSCLC treated with afatinib
by: Chen‐Te Wu, et al.
Published: (2023-09-01)

Long‐term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation‐positive lung adenocarcinoma
by: Naoki Shijubou, et al.
Published: (2021-03-01)

Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Advanced Nonsmall Cell Lung Cancer Patients
by: Yan-Jei Tang, et al.
Published: (2024-01-01)

Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
by: Chiao-En Wu, et al.
Published: (2021-07-01)

Toxic epidermal necrosis associated with afatinib: A case report and literature review
by: Wei Yang, et al.
Published: (2023-01-01)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib
by: Sami Morin-Ben Abdallah, et al.
Published: (2017-05-01)

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
by: Chih-Jen Yang, et al.
Published: (2017-12-01)

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients
by: John Wen‐Cheng Chang, et al.
Published: (2022-07-01)

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
by: Wei Dong, et al.
Published: (2022-11-01)

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
by: John Wen‐Cheng Chang, et al.
Published: (2023-01-01)

Prospective exosome‐focused translational research for afatinib study of non‐small cell lung cancer patients expressing EGFR (EXTRA study)
by: Yusuke Okuma, et al.
Published: (2019-02-01)

Afatinib-induced acneiform eruptions
by: Twinkle Singh Thakur, et al.
Published: (2022-01-01)

Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low‐dose afatinib: A case report
by: Yuko Iida, et al.
Published: (2020-02-01)

The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study
by: Wen-Chien Cheng, et al.
Published: (2024-02-01)

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations
by: Yi-Chieh Chen, et al.
Published: (2021-05-01)

Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides
by: Shu-Ting Hong, et al.
Published: (2019-08-01)

An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece
by: Mountzios G, et al.
Published: (2021-08-01)

Targeting human epidermal growth factor receptor 2 enhances radiosensitivity and reduces the metastatic potential of Lewis lung carcinoma cells
by: Yun Tien, et al.
Published: (2020-03-01)

Stimulation of Eryptosis by Afatinib
by: Abdulla Al Mamun Bhuyan, et al.
Published: (2018-06-01)

Second-line afatinib administration in an elderly patient with squamous cell carcinoma
by: Hohenforst-Schmidt W, et al.
Published: (2017-03-01)

Adverse Events of Afatinib as First-line Treatment for Five Cases of Advanced Lung Adenocarcinoma and Review of Literature
by: Hong TAO, et al.
Published: (2014-04-01)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
by: Yingying Jiang, et al.
Published: (2023-05-01)

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
by: Gwo-Fuang Ho, et al.
Published: (2019-09-01)

Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer
by: Kazumi Sano, et al.
Published: (2020-04-01)

Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan
by: Jerry Shu-Hung Kuo, et al.
Published: (2025-01-01)

Successful treatment of a patient with NSCLC carrying uncommon compound L861Q/G719X epidermal growth factor receptor mutations using Afatinib
by: Zihan Zhou, et al.
Published: (2024-01-01)

Medication adjustment of afatinib and combination therapy with sitagliptin for alleviating afatinib-induced diarrhea in rats
by: Li Zhang, et al.
Published: (2023-09-01)

Afatinib Sensibilizes Multidrug-resistant Human Ovarian Cancer Cells to Adriamycin and Related Mechanisms
by: ZHANG Yunqi, et al.
Published: (2018-10-01)

“Liquid elbows” due to afatinib administration
by: Paul Zarogoulidis, et al.
Published: (2017-01-01)

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study
by: Suey-Haur Lee, et al.
Published: (2022-07-01)

Recent Management of Patients with Advanced Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer: Role of Afatinib and Lesson Learned for Developing Countries
by: Zulkifli Amin, et al.
Published: (2017-04-01)

Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
by: Wang Chun Kwok, et al.
Published: (2022-07-01)

Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions
by: Ping-Chih Hsu, et al.
Published: (2016-04-01)

A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib
by: Dong Chen, et al.
Published: (2020-06-01)

A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
by: Chun-Yao Huang, et al.
Published: (2023-05-01)

Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far
by: Xu Y, et al.
Published: (2016-05-01)

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors
by: Ping-Chih Hsu, et al.
Published: (2023-10-01)